Table 1 The correlation between the amount of tRF-29-79MP9P9NH525 in tissues and clinicopathological features of advanced gastric cancer patients.

From: Correction to: Identification of tRF-29-79MP9P9NH525 as a biomarker and tumor suppressor of gastric cancer via regulating KIF14/AKT pathway

Characteristics

n (%)

High (%)

Low (%)

P-value

All cases

119

59

60

 

Gender

   

>0.9999

Male

71 (59.66)

35 (59.32)

36 (60.00)

 

Female

48 (40.34)

24 (40.68)

24 (40.00)

 

Age (y)

   

0.1627

≥60

83 (69.75)

45 (76.27)

38 (63.33)

 

<60

36 (30.25)

14 (23.73)

22 (36.67)

 

Differentiation

   

0.0107

Well

9 (7.56)

5 (8.48)

4 (6.67)

 

Moderate

68 (57.14)

41 (69.49)

27 (45.00)

 

Poor

42 (35.30)

13 (22.03)

29 (48.33)

 

Lymphatic node metastasis

   

>0.9999

N0

37 (31.09)

18 (30.51)

19 (31.67)

 

N1 & N2 & N3

82 (68.91)

41 (69.49)

41 (68.33)

 

Invasion

   

0.1563

T2

39 (32.77)

20 (33.90)

19 (31.67)

 

T3

7 (5.88)

1 (1.69)

6 (10.00)

 

T4

73 (61.35)

38 (64.41)

35 (58.33)

 

Tumor size (cm)

   

0.0278

≥5

63 (52.94)

25 (42.37)

38 (63.33)

 

<5

56 (47.06)

34 (57.63)

22 (36.67)

 

Distal metastasis

   

0.3644

Yes

4 (3.36)

3 (5.08)

1 (1.67)

 

No

115 (96.64)

56 (94.92)

59 (98.33)

 

TNM stage

   

0.6373

IB

25 (21.00)

13 (22.03)

12 (20.00)

 

IIA & IIB

24 (20.17)

10 (16.95)

14 (23.33)

 

IIIA & IIIB & IIIC

66 (55.46)

33 (55.93)

33 (55.00)

 

IV

4 (3.36)

3 (5.09)

1 (1.67)

 

Vessel invasion

   

>0.9999

Yes

85 (71.43)

42 (71.19)

43 (71.67)

 

No

34 (28.57)

17 (28.81)

17 (28.33)

 

Lymphatic invasion

   

0.6883

Yes

84 (70.59)

43 (72.88)

41 (68.33)

 

No

35 (29.41)

16 (27.12)

19 (31.67)

 

Nerve invasion

   

0.0877

Yes

76 (63.87)

33 (55.93)

43 (71.67)

 

No

43 (36.13)

26 (44.07)

17 (28.33)

 

Ki-67 (%)

   

0.3689

>30

94 (78.99)

49 (83.05)

45 (75.00)

 

≤30

25 (21.01)

10 (16.95)

15 (25.00)